Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $107K rose 8.1% year over year, ahead of the -11.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 40.8% from the prior quarter. Over 3 fiscal years it compounded at +42.8% a year.

Context

  • Depreciation & amortization amounted to 21.0% of revenue in FY2025, up 14.4 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.1% holds above the trailing-twelve-month pace of -11.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$107K+40.8% QoQ
Last fiscal yearDec 2025
$428K+3.9% YoY
LTMJun 2026
$379K-11.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.1%——
1 year+3.9%——
3-year CAGR+42.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
428K USD
Year-over-year change
+3.9%
4-year CAGR
-32.2%

Depreciation & Amortization vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's LTM Jun 2026 depreciation & amortization of $379K is the 8th highest of the 10 companies compared; the peer median is $2.42M.
  • Its year-over-year change of -11.0% is the 8th highest of 10, against a peer median of +6.6%.
  • Depreciation & amortization amounts to 19.9% of revenue for DNTH, versus a peer median of 20.6%.
DNTH Competitors Peer median
Depreciation & Amortization for DNTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$3.08M +50.1%+151.3%—
ALMSAlumis Inc. Common StockLTM Jun 2026$2.65M -20.7%+140.9%35.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.64M +6.6%+30.9%—
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M +1.2%+1.2%1.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M +13.8%+13.3%136.2%
CNTBConnect Biopharma Holdings LimitedFY2025$704K +6.7%-11.9%1100.0%
VERAVera Therapeutics, Inc.LTM Jun 2026$536K +89.4%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$379K -11.0%+42.8%19.9%
IMVTImmunovant, Inc.LTM Sep 2026$378K -10.0%+28.4%5.3%
QTTBQ32 Bio Inc.LTM Mar 2026$362K -25.1%+1.9%0.7%
Peer median (excluding DNTH) $2.42M+6.6%+20.8%20.6%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.48M6.42M2.83M6.24M2.04M
Cost of Revenue00000
Gross Profit1.48M6.42M2.83M6.24M2.04M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development12.61M29.38M32.84M83.11M145.64M
Selling, General & Admin1.96M6.74M18.16M24.99M34.33M
Operating Expenses14.56M36.12M51M108.1M179.97M
Depreciation & Amortization2.02M147K355K412K428K
EBITDA(11.09M)(28.33M)(43.2M)(84.56M)(161.91M)
EBITDA Margin-751.3%-441.5%-1528.7%-1356.2%-7952.3%
Operating Income(13.09M)(29.71M)(48.17M)(101.86M)(177.93M)
Operating Margin-886.6%-462.9%-1704.7%-1633.7%-8739.3%
Interest Income100K1.15M4.76M17.37M16.12M
Interest Expense00000
Other Income / Expenses(23K)1.23M4.62M16.9M15.6M
Income Before Tax(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Pre-Tax Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
Income Tax Expense00000
Net Income(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Net Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
EPS (Basic)(3.82)(7.60)(8.45)(2.55)(4.20)
EPS (Diluted)(3.82)(7.60)(8.45)(2.55)(4.20)
Weighted Avg Shares3.43M3.75M5.15M33.31M37.79M
Weighted Avg Shares (Diluted)3.43M3.75M5.15M33.31M37.79M

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.